|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Qiu T, Zhou L, Wang T, Xu J, Wang J, Chen
W, Zhou X, Huang Z, Zhu W, Shu Y, et al: miR-503 regulates the
resistance of non-small cell lung cancer cells to cisplatin by
targeting Bcl-2. Int J Mol Med. 32:593–598. 2013.PubMed/NCBI
|
|
3
|
Fojo T: Multiple paths to a drug
resistance phenotype: Mutations, translocations, deletions and
amplification of coding genes or promoter regions, epigenetic
changes and microRNAs. Drug Resist Updat. 10:59–67. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Glasspool RM, Teodoridis JM and Brown R:
Epigenetics as a mechanism driving polygenic clinical drug
resistance. Br J Cancer. 94:1087–1092. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Sharma SV, Lee DY, Li B, Quinlan MP,
Takahashi F, Maheswaran S, McDermott U, Azizian N, Zou L, Fischbach
MA, et al: A chromatin-mediated reversible drug-tolerant state in
cancer cell subpopulations. Cell. 141:69–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993.
|
|
7
|
Hobert O: Gene regulation by transcription
factors and microRNAs. Science. 319:1785–1786. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Griffiths-Jones S, Saini HK, van Dongen S
and Enright AJ: miRBase: Tools for microRNA genomics. Nucleic Acids
Res. 36:D154–D158. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhao JJ, Yang J, Lin J, Yao N, Zhu Y,
Zheng J, Xu J, Cheng JQ, Lin JY and Ma X: Identification of miRNAs
associated with tumorigenesis of retinoblastoma by miRNA microarray
analysis. Childs Nerv Syst. 25:13–20. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Peng Y, Liu YM, Li LC, Wang LL and Wu XL:
microRNA-503 inhibits gastric cancer cell growth and
epithelial-to-mesenchymal transition. Oncol Lett. 7:1233–1238.
2014.PubMed/NCBI
|
|
11
|
Chong Y, Zhang J, Guo X, Li G, Zhang S, Li
C, Jiao Z and Shao M: MicroRNA-503 acts as a tumor suppressor in
osteosarcoma by targeting L1CAM. PLoS One. 9:e1145852014.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang Y, Chen X, Lian H, Liu J, Zhou B,
Han S, Peng B, Yin J, Liu W and He X: MicroRNA-503 acts as a tumor
suppressor in glioblastoma for multiple antitumor effects by
targeting IGF-1R. Oncol Rep. 31:1445–1452. 2014.PubMed/NCBI
|
|
13
|
Wang T, Ge G, Ding Y, Zhou X, Huang Z, Zhu
W, Shu Y and Liu P: miR-503 regulates cisplatin resistance of human
gastric cancer cell lines by targeting IGF1R and BCL2. Chin Med J
(Engl). 127:2357–2362. 2014.PubMed/NCBI
|
|
14
|
Sunavala-Dossabhoy G, Palaniyandi S, Clark
C, Nathan CO, Abreo FW and Caldito G: Analysis of eIF4E and 4EBP1
mRNAs in head and neck cancer. Laryngoscope. 121:2136–2141. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Singh J, Jayaraj R, Baxi S, Mileva M,
Curtin J and Thomas M: An Australian retrospective study to
evaluate the prognostic role of p53 and eIF4E cancer markers in
patients with head and neck squamous cell carcinoma (HNSCC): Study
protocol. Asian Pac J Cancer Prev. 14:4717–4721. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yin X, Kim RH, Sun G, Miller JK and Li BD:
Overexpression of eukaryotic initiation factor 4E is correlated
with increased risk for systemic dissemination in node-positive
breast cancer patients. J Am Coll Surg. 218:663–671. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Garzon R, Marcucci G and Croce CM:
Targeting microRNAs in cancer: Rationale, strategies and
challenges. Nat Rev Drug Discov. 9:775–789. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Chen GQ, Zhao ZW, Zhou HY, Liu YJ and Yang
HJ: Systematic analysis of microRNA involved in resistance of the
MCF-7 human breast cancer cell to doxorubicin. Med Oncol.
27:406–415. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Y, Li W, Yang Y, Lu Y, He C, Hu G, Liu
H, Chen J, He J and Yu H: MicroRNA-21 targets LRRFIP1 and
contributes to VM-26 resistance in glioblastoma multiforme. Brain
Res. 1286:13–18. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xu K, Liang X, Cui D, Wu Y, Shi W and Liu
J: miR-1915 inhibits Bcl-2 to modulate multidrug resistance by
increasing drug-sensitivity in human colorectal carcinoma cells.
Mol Carcinog. 52:70–78. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Xia L, Zhang D, Du R, Pan Y, Zhao L, Sun
S, Hong L, Liu J and Fan D: miR-15b and miR-16 modulate multidrug
resistance by targeting BCL2 in human gastric cancer cells. Int J
Cancer. 123:372–379. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen J, Tian W, Cai H, He H and Deng Y:
Downregulation of microRNA-200c is associated with drug resistance
in human breast cancer. Med Oncol. 29:2527–2534. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
He H, Tian W, Chen H and Deng Y:
MicroRNA-101 sensitizes hepatocellular carcinoma cells to
doxorubicin-induced apoptosis via targeting Mcl-1. Mol Med Rep.
13:1923–1929. 2016.PubMed/NCBI
|
|
24
|
Xu Y, Huang J, Ma L, Shan J, Shen J, Yang
Z, Liu L, Luo Y, Yao C and Qian C: MicroRNA-122 confers sorafenib
resistance to hepatocellular carcinoma cells by targeting IGF-1R to
regulate RAS/RAF/ERK signaling pathways. Cancer Lett. 371:171–181.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Long J, Ou C, Xia H, Zhu Y and Liu D:
MiR-503 inhibited cell proliferation of human breast cancer cells
by suppressing CCND1 expression. Tumour Biol. 36:8697–8702. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yang Y, Liu L, Zhang Y, Guan H, Wu J, Zhu
X, Yuan J and Li M: MiR-503 targets PI3K p85 and IKK-β and
suppresses progression of non-small cell lung cancer. Int J Cancer.
135:1531–1542. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Xiao F, Zhang W, Chen L, Chen F, Xie H,
Xing C, Yu X, Ding S, Chen K, Guo H, et al: MicroRNA-503 inhibits
the G1/S transition by downregulating cyclin D3 and E2F3 in
hepatocellular carcinoma. J Transl Med. 11:1952013. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Xu YY, Wu HJ, Ma HD, Xu LP, Huo Y and Yin
LR: MicroRNA-503 suppresses proliferation and cell-cycle
progression of endometrioid endometrial cancer by negatively
regulating cyclin D1. FEBS J. 280:3768–3779. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Forrest AR, Kanamori-Katayama M, Tomaru Y,
Lassmann T, Ninomiya N, Takahashi Y, de Hoon MJ, Kubosaki A, Kaiho
A, Suzuki M, et al: Induction of microRNAs, miR-155, miR-222,
miR-424 and miR-503, promotes monocytic differentiation through
combinatorial regulation. Leukemia. 24:460–466. 2010. View Article : Google Scholar : PubMed/NCBI
|
